Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Linda Henry

Showing results (201-210 of 278) with videos related to

Pageof 28
Sort By:
JAMA Network Open|October 20, 2025
County-Level Factors and Preventable Premature Liver Mortality in Metabolic Dysfunction-Associated Steatotic Liver DiseaseJames M Paik, Shira Zelber-Sagi, Annette Paik, et al.
JAMA Network Open|April 10, 2020
Diagnosis Rates of Chronic Hepatitis B in Privately Insured Patients in the United StatesEiichi Ogawa, Yee Hui Yeo, Nolan Dang, et al.
European Journal of Gastroenterology & Hepatology|September 7, 2019
Only one-third of hepatocellular carcinoma cases are diagnosed via screening or surveillance: a systematic review and meta-analysisChangqing Zhao, Feng Xing, Yee Hui Yeo, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 10, 2013
Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis CZobair M Younossi, Maria Stepanova, Linda Henry, et al.
Alimentary Pharmacology & Therapeutics|February 23, 2023
Editorial: let's get physical-long-term benefits of vigorous physical activity in patients with nonalcoholic fatty liver disease. Authors' replyAustin Henry, James M Paik, Patrick Austin, et al.
Hepatology Communications|December 21, 2023
The changing epidemiology of adult liver transplantation in the United States in 2013-2022: The dominance of metabolic dysfunction-associated steatotic liver disease and alcohol-associated liver diseaseZobair M Younossi, Maria Stepanova, Reem Al Shabeeb, et al.
Journal of Gastroenterology and Hepatology|July 22, 2014
Single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)Munkhzul Otgonsuren, Michael J Estep, Nayeem Hossain, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|July 17, 2025
Steatotic liver disease is the dominant indication for liver transplantation in both Europe and the United States: Trends and outcomes in the past 2 decadesZobair M Younossi, Giacomo Germani, Robert Wong, et al.
Journal of Clinical Gastroenterology|January 31, 2025
Focused Recommendations for the Management of Metabolic Dysfunction-Associated Steatohepatitis (MASH) by Advanced Practice Providers in the United StatesBrian P Lam, Jessica Bartholomew, Sherona Bau, et al.
The Journal of Infectious Diseases|July 9, 2018
Reduced Incidence of Hepatocellular Carcinoma in Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis B Treated With Tenofovir-A Propensity Score-Matched StudyMindie H Nguyen, Hwai-I Yang, An Le, et al.
Pageof 28

Showing results (201-210 of 278) with videos related to

Sort By:
Pageof 28
JAMA Network Open|October 20, 2025
County-Level Factors and Preventable Premature Liver Mortality in Metabolic Dysfunction-Associated Steatotic Liver DiseaseJames M Paik, Shira Zelber-Sagi, Annette Paik, et al.
JAMA Network Open|April 10, 2020
Diagnosis Rates of Chronic Hepatitis B in Privately Insured Patients in the United StatesEiichi Ogawa, Yee Hui Yeo, Nolan Dang, et al.
European Journal of Gastroenterology & Hepatology|September 7, 2019
Only one-third of hepatocellular carcinoma cases are diagnosed via screening or surveillance: a systematic review and meta-analysisChangqing Zhao, Feng Xing, Yee Hui Yeo, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 10, 2013
Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis CZobair M Younossi, Maria Stepanova, Linda Henry, et al.
Alimentary Pharmacology & Therapeutics|February 23, 2023
Editorial: let's get physical-long-term benefits of vigorous physical activity in patients with nonalcoholic fatty liver disease. Authors' replyAustin Henry, James M Paik, Patrick Austin, et al.
Hepatology Communications|December 21, 2023
The changing epidemiology of adult liver transplantation in the United States in 2013-2022: The dominance of metabolic dysfunction-associated steatotic liver disease and alcohol-associated liver diseaseZobair M Younossi, Maria Stepanova, Reem Al Shabeeb, et al.
Journal of Gastroenterology and Hepatology|July 22, 2014
Single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)Munkhzul Otgonsuren, Michael J Estep, Nayeem Hossain, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|July 17, 2025
Steatotic liver disease is the dominant indication for liver transplantation in both Europe and the United States: Trends and outcomes in the past 2 decadesZobair M Younossi, Giacomo Germani, Robert Wong, et al.
Journal of Clinical Gastroenterology|January 31, 2025
Focused Recommendations for the Management of Metabolic Dysfunction-Associated Steatohepatitis (MASH) by Advanced Practice Providers in the United StatesBrian P Lam, Jessica Bartholomew, Sherona Bau, et al.
The Journal of Infectious Diseases|July 9, 2018
Reduced Incidence of Hepatocellular Carcinoma in Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis B Treated With Tenofovir-A Propensity Score-Matched StudyMindie H Nguyen, Hwai-I Yang, An Le, et al.
Pageof 28